Ethical questions in functional neuroimaging and cognitive enhancement

Poiesis und Praxis

Volumn 4, Issue 2, 2006, Pages 81-94

  Turner, Danielle C ^a   Sahakian, Barbara J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745105970     PISSN: 16156609     EISSN: 16156617     Source Type: Journal    
DOI: 10.1007/s10202-005-0020-1     Document Type: Article

References (60)

1. Ambrose PJ (1997) Doping control in sports - a perspective from the 1996 Olympic Games. Am J Health Syst Pharm 54:1053-1057
2. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J (2005) Cost of disorders of the brain in Europe. Eur J Neurol 12(Suppl 1):1-27
3. Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003) Methylphenidate improves response inhibition in adults with attention-deficit/ hyperactivity disorder. Biol Psychiatry 54:1465-1468
4. Associated Press (2004) Scientists scan brains for political clues. Associated Press via CNN. http://www.olm.blythe-systems.com/pipermail/ nytr/Week-of-Mon-20041101/008470.html Accessed 5 January 2005
5. Babcock Q, Byrne T (2000) Student perceptions of methylphenidate abuse at a public liberal arts college. J Am Coll Health 49:143-145
6. BBC News (2004) Mentally ill man executed in US. http://www.news.bbc.co.uk/1/hi/world/americas/3374831.stm Accessed 7 January 2004
7. Beauchamp T, Walters L (2002) Contemporary issues in bioethics. Wadsworth Publishing Company, Belmont, California
8. Boire RG, Ruiz-Sierra J (2003) Supreme Court upholds right to refuse mind-altering drugs. http://www.cognitiveliberty.org/news/ US_v_Sell_decision.htm Accessed 31 August 2004
9. Brown D (2000) Performance maintenance during continuous flight operations. A guide for flight surgeons NAVMED P-6410. 1st edn. Naval Aerospace Medical Research Laboratory, Penascola, Florida
10. Butcher J (2003) Cognitive enhancement raises ethical concerns. Academics urge pre-emptive debate on neurotechnologies. Lancet 362:132-133
11. Canli T, Amin Z (2002) Neuroimaging of emotion and personality: scientific evidence and ethical considerations. Brain Cogn 50:414-431
12. Caplan A (2002) No-Brainer: Can we cope with the ethical ramifications of new Mnowledge of the human brain? In: Neuroethics: mapping the field conference proceedings, San Francisco, California. The Dana Press, New York, 13-14 May 2002, pp 95-106
13. Cardenas DD, McLean A Jr, Farrell-Roberts L, Baker L, Brooke M, Haselkorn J (1994) Oral physostigmine and impaired memory in adults with brain injury. Brain Inj 8:579-587
14. Carlezon WA, Jnr, Konradi C (2004) Understanding the neurobiological consequences of early exposure to psychotropic drugs: Linking behavior with molecules. Neuropharmacology 47:47-60
15. Dale JR, Appelbe GE, Wingfield J (2001) Dale and Appelbe's Pharmacy Law and Ethics, 7th edn. Pharmaceutical Press, London
16. Duka T, Sahakian BJ, Turner DC (2005) Experimental psychology and research into brain science, Addiction and Drugs http://www.foresight.gov.uk/Brain_Science_Addiction_and_Drugs/ Reports_and_Publications/ScienceReviews/Experimental%20Psychology.pdf Accessed 13 July 2005
17. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW (1997) Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology (Berl) 131:196-206
18. Farah MJ (2002) Emerging ethical issues in neuroscience. Nat Neurosci 5:1123-1129
19. Farah MJ, Illes J, Cook-Deegan R, Gardner H, Kandel E, King P, Parens E, Sahakian B, Wolpe PR (2004) Neurocognitive enhancement: What can we do and what should we do? Nat Rev Neurosci 5:421-425
20. Farah MJ, Wolpe PR (2004) Monitoring and manipulating brain function: new neuroscience technologies and their ethical implications. Hastings Cent Rep 34:35-45
21. Ganis G, Kosslyn SM, Stose S, Thompson WL, Yurgelun-Todd DA (2003) Neural correlates of different types of deception: An fMRI investigation. Cereb Cortex 13:830-836
22. Garoff RJ, Slotnick SD, Schacter DL (2005) The neural origins of specific and general memory: The role of the fusiform cortex. Neuropsychologia 43:847-859
23. Geyer MA, Tamminga CA (2004) Measurement and treatment research to improve cognition in schizophrenia: Neuropharmacological aspects. Psychopharmacology 174:1-2
24. Gillon R (1994) Medical ethics: Four principles plus attention to scope. BMJ 309:184-188
25. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, Schulz SC, Weinberger DR (1993) The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48
26. Illes J (2003) Neuroethics in a new era of neuroimaging. Am J Neuroradiol 24:1739-1741
27. Illes J, Kirschen MP, Gabrieli JD (2003) From neuroimaging to neuroethics. Nat Neurosci 6:205
28. Illes J, Racine E (2005) Imaging or imagining? A neuroethics challenge informed by genetics. Am J Bioeth 5:5-18
29. Kiehl KA, Smith AM, Mendrek A, Forster BB, Hare RD, Liddle PF (2004) Temporal lobe abnormalities in semantic processing by criminal psychopaths as revealed by functional magnetic resonance imaging. Psychiatry Res 130:297-312
30. Kuhse H, Singer P (2001) A companion to bioethics. Blackwell Publishers, Oxford
31. Langleben DD, Loughead JW, Bilker WB, Ruparel K, Childress AR, Busch SI, Gur RC (2005) Telling truth from lie in individual subjects with fast event-related fMRI. Hum Brain Mapp 26(4):262-272
32. Langleben DD, Schroeder L, Maldjian JA, Gur RC, McDonald S, Ragland JD, O'Brien CP, Childress AR (2002) Brain activity during simulated deception: An event-related functional magnetic resonance study. Neuroimage 15:727-732
33. Leshner AI (2005) It's time to go public with neuroethics. Am J Bioeth 5(2):1-4
34. Lorberbaum JP, Bohning DE, Shastri A, Nahas Z, George MS (2004) Functional magnetic resonance imaging for the psychiatrist. http://www.musc.edu/psychiatry/fnrd/primer_fmri.htm Accessed 5 October 2004
35. Mann EM, Ikeda Y, Mueller CW, Takahashi A, Tao KT, Humris E, Li BL, Chin D (1992) Cross-cultural differences in rating hyperactive-disruptive behaviors in children. Am J Psychiatry 149:1539-1542
36. Marcus M (2002) In: Neuroethics: mapping the field conference proceedings, San Francisco, California. The Dana Press, New York, 13-14 May 2002
37. McCabe SE, Knight JR, Teter CJ, Wechsler H (2005) Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction 100:96-106
38. McClure SM, Li J, Tomlin D, Cypert KS, Montague LM, Montague PR (2004) Neural correlates of behavioral preference for culturally familiar drinks. Neuron 44:379-87
39. McDowell S, Whyte J, D'Esposito M (1998) Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain 121:1155-1164
40. Mehta MA, Calloway P, Sahakian BJ (2000) Amelioration of specific working memory deficits by methylphenidate in a case of adult attention deficit/hyperactivity disorder. J Psychopharmacol 14:299-302
41. Mitchell RL, Elliott R, Woodruff PW (2001) fMRI and cognitive dysfunction in schizophrenia. Trends Cogn Sci 5:71-81
42. Moll J, de Oliveira-Souza R, Moll FT, Ignacio FA, Bramati IE, Caparelli-Daquer EM, Eslinger PJ (2005) The moral affiliations of disgust: A functional MRI study. Cogn Behav Neurol 18:68-78
43. National Audit Office (2003) Safety, quality and efficacy: Regulating medicines in the UK. In: Report by the Comptroller and Auditor General HC 255. The Stationery Office, London
44. Parens E (2002) How far will the term enhancement get us as we grapple with neM ways to shape ourselves? In: Neuroethics: mapping the field conference proceedings, San Francisco, California. The Dana Press, New York, 13-14 May 2002, pp 152-158
45. Phelps EA, O'Connor KJ, Cunningham WA, Funayama ES, Gatenby JC, Gore JC, Banaji MR (2000) Performance on indirect measures of race evaluation predicts amygdala activation. J Cogn Neurosci 12:729-738
46. Racine E, Bar-Ilan O, Illes J (2005) fMRI in the public eye. Nat Rev Neurosci 6:159-164
47. Rahman S, Robbins TW, Hodges JR, Mehta MA, Nestor PJ, Clark L, Sahakian BJ (2005) Methylphenidate ('Ritalin') can ameliorate abnormal risk-taking behaviour in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. Advanced online publication, 7 September 2005, doi:10.1038/sj.npp.1300886
48. Rappley MD, Gardiner JC, Jetton JR, Houang RT (1995) The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med 149:675-679
49. Robbins TW, McAlonan G, Muir JL, Everitt BJ (1997) Cognitive enhancers in theory and practice: Studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behav Brain Res 83:15-23
50. Singer T, Seymour B, O'Doherty J, Kaube H, Dolan RJ, Frith CD (2004) Empathy for pain involves the affective but not sensory components of pain. Science 303:1157-1162
51. Sonuga-Barke EJS, Minocha K, Taylor EA, Sandberg S (1993) Inter-ethnic bias in teachers ratings of childhood hyperactivity. Br J Dev Psychol 11:187-200
52. Stark CE, Squire LR (2001) When zero is not zero: The problem of ambiguous baseline conditions in fMRI. Proc Natl Acad Sci USA 98:12760-12766
53. Timimi S, Moncrieff J, Jureidini J, Leo J, Cohen D, Whitfield C, Double D, Bindman J, Andrews H, Asen E, Bracken P, Duncan B, Dunlap M, Albert G, Green M, Greening T, Hill J, Huws R, Karon B, Kean B, McCubbin M, Miatra B, Mosher L, Parry S, DuBose Ravenel S, Riccio D, Shulman R, Stolzer J, Thomas P, Vimpani G, Wadsworth A, Walker D, Wetzel N, White R (2004) A critique of the international consensus statement on ADHD (discussion 65-69). Clin Child Fam Psychol Rev 7:59-63
54. Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ (2005) Neurocognitive effects of methylphenidate in adult attention-deficit/ hyperactivity disorder. Psychopharmacology (Berl) 178:286-295
55. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ (2004a) Modafinil improves cognition and response inhibition in adult attention-deficit/ hyperactivity disorder. Biol Psychiatry 55:1031-1040
56. Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004b) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29:1363-1373
57. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ (2003) Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165:260-269
58. Turner DC, Sahakian BJ (2005) The neuroethics of cognitive enhancement. BioSocieties (in press)
59. Wesensten NJ, Belenky G, Kautz MA, Thorne DR, Reichardt RM, Balkin TJ (2002) Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl) 159:238-247
60. Wolpe PR, Foster KR, Langleben DD (2005) Emerging neurotechnologies for lie-detection: Promises and perils. Am J Bioeth 5:39-49